Allelic Loss of the Active X Chromosome during Bladder Carcinogenesis

Archives of Pathology and Laboratory Medicine

Volumn 128, Issue 2, 2004, Pages 187-190

  Cheng, Liang ^a,c   MacLennan, Gregory T ^b   Pan, Chong Xian ^a   Jones, Timothy D ^a   Moore, Curtiss R ^a   Zhang, Shaobo ^a   Gu, Jian ^a   Patel, Namrata B ^a   Kao, Chinghai ^a   Gardner, Thomas A ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c INDIANA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR;

ALLELE; ARTICLE; BLADDER CANCER; BLADDER CARCINOGENESIS; CANCER GROWTH; CANCER INVASION; CARCINOMA IN SITU; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTECTOMY; FEMALE; GENE DELETION; GENE LOCUS; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; UROGENITAL TRACT TUMOR; X CHROMOSOME INACTIVATION; X CHROMOSOME LINKAGE;

CARCINOMA; CHROMOSOMES, HUMAN, X; FEMALE; HUMANS; LOSS OF HETEROZYGOSITY; RECEPTORS, ANDROGEN; URINARY BLADDER NEOPLASMS;

EID: 10744225524     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Dalbagni G, Presti J, Reuter V, Fair WR, Cordon-Cardo C. Genetic alterations in bladder cancer. Lancet. 1993;342:469-471.
2. Spruck CH, Ohneseit PF, Gonzalez-Zulueta M, et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res. 1994;54:784-788.
3. Droller MJ. Bladder cancer: state-of-the-art care. CA Cancer J Clin. 1998; 48:269-284.
4. Habuchi T, Devlin J, Elder PA, Knowles MA. Detailed deletion mapping of chromosome 9q in bladder cancer: evidence for two tumour suppressor loci. Oncogene. 1995;11:1671-1174.
5. Miyao N, Tsai YC, Lerner SP, et al. Role of chromosome 9 in human bladder cancer. Cancer Res. 1993;53:4066-4070.
6. Cheng L, Bostwick DG, Li G, Zhang S, Vortmeyer AO, Zhuang Z. Conserved genetic findings in metastatic bladder cancer: a possible utility of allelic loss of chromosome 9p21 and 17p13 in diagnosis. Arch Pathol Lab Med. 2001;125: 1197-1199.
7. Orlow I, Lianes P, Lacombe L, Dalbagni G, Reuter VE, Cordon-Cardo C. Chromosome 9 allelic losses and microsatellite alterations in human bladder tumors. Cancer Res. 1994;54:2848-2851.
8. Knowles MA, Elder PA, Williamson M, Cairns JP, Shaw ME, Law MG. Allelotype of human bladder cancer. Cancer Res. 1994;54:531-538.
9. Cheng PC, Gosewehr JA, Kim TM, et al. Potential role of the inactivated X chromosome in ovarian epithelial tumor development. J Natl Cancer Inst. 1996; 88:510-518.
10. D'adda T, Candidus S, Denk H, Bordi C, Hofler H. Gastric neuroendocrine neoplasms: tumour clonality and malignancy-associated large X-chromosomal deletions. J Pathol. 1999;189:394-401.
11. Osborne RJ, Leech V. Polymerase chain reaction allelotyping of human ovarian cancer. Br J Cancer 1994;69:429-438.
12. Brown CJ. Role of the X-chromosome in cancer. J Natl Cancer Inst. 1996; 88:480-482.
13. Cliby W, Ritland S, Hartmann L, Dodson M, Halling KC, Kenney G. Human epithelial ovarian cancer allelotype. Cancer Res. 1993;53:2393-2398.
14. Yang-Feng TL, Li S, Han H, Schwartz PE. Frequent loss of heterozygosity on chromosomes Xp and 13q in human ovarian epithelial tumor development. Int J Cancer. 1992;52:575-580.
15. Cheng L, Song SY, Pretlow TG, et al. Evidence of independent origin of multiple tumors from prostate cancer patients. J Natl Cancer Inst. 1998;90:233-237.
16. Cheng L, Shan A, Cheville JC, Qian J, Bostwick DG. Atypical adenomatous hyperplasia of the prostate: a premalignant lesion? Cancer Res. 1998;58:389-391.
17. Gu J, Roth LM, Younger C, et al. Molecular evidence for the independent origin of extra-ovarian papillary serous tumors of low malignant potential. J Natl Cancer Inst. 2001;93:1147-1152.
18. Cheng L, Gu J, Eble JN, et al. Molecular genetic evidence for different clonal origin of components of human renal angiomyolipoma. Am J Surg Pathol. 2001;25:1231-1236.
19. Brandli DW, Ulbright TM, Foster RS, et al. Stroma adjacent to metastatic mature teratoma after chemotherapy for testicular germ cell tumor is derived from the same progenitor cells as the teratoma. Cancer Res. 2003;63:6063-6068.
20. Kernek KM, Ulbright TM, Zhang S, et al. Identical allelic loss in mature teratoma and different histologic components of malignant mixed germ cell tumors of the testis. Am J Pathol. 2003;163:2477-2484.
21. Younger C, Ulbright TM, Zhang S, et al. Molecular evidence supporting the neoplastic nature of some epidermoid cysts of the testis. Arch Pathol Lab Med. 2003;127:858-860.
22. Cheng L, Bostwick DG, Li G, et al. Allelic imbalance in the clonal evolution of prostate carcinoma. Cancer. 1999;85:2017-2022.
23. Knudson AG. Antioncogenes and human cancer. Proc Natl Acad Sci U S A. 1993;90:10914-10921.
24. Cheng L, Cheville JC, Leibovich BC, et al. Survival of patients with carcinoma in situ of the urinary bladder. Cancer. 1999;85:2469-2474.
25. Wang XW, Lin X, Klein CB, Bhamra RK, Lee YW, Costa M. A conserved region in human and Chinese hamster X chromosomes can induce cellular senescence of nickel-transformed Chinese hamster cell lines. Carcinogenesis. 1992; 13:555-561.
26. Klein CB, Conway K, Wang XW, et al. Senescence of nickel-transformed cells by an X chromosome: possible epigenetic control. Science. 1991;251:796-799.
27. Maestrini E, Tamanini F, Kioschis P, et al. An archipelago of CpG islands in Xq28: identification and fine mapping of 20 new CpG islands of the human X chromosome. Hum Mol Genet. 1992;1:275-280.
28. Wolf SF, Migeon BR. Clusters of CpG dinucleotides implicated by nuclease hypersensitivity as control elements of housekeeping genes. Nature. 1985;314: 467-469.
29. Venolia L, Gartler SM. Comparison of the transformation frequency of human active and inactive X-chromosome DNA. Nature. 1983;302:82-83.
30. Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet. 1999; 21:163-167.
31. Baylin SB, Belinsky SA, Herman JG. Aberrant methylation of gene promoters in cancer-concepts, misconcepts, and promise. J Natl Cancer Inst. 2000; 92:1460-1461.
32. Salem C, Liang G, Tsai YC, et al. Progressive increase in de novo methylation of CpG islands in bladder cancer. Cancer Res. 2000;60:2473-2476.
33. Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin SB, Herman JG. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA form non-small cell lung cancer patients. Cancer Res. 1999; 59:67-70.
34. Tang X, Khuri FR, Lee JJ, et al. Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer. J Natl Cancer Inst. 2000;92:1511-1516.
35. Myohanen SK, Baylin SB, Herman JG. Hypermethylation can selectively silence individual p16INK4a alleles in neoplasia. Cancer Res. 1998;58:591-593.
36. Esteller M, Fraga MF, Paz MF, et al. Cancer epigenetics and methylation. Science. 2002;297:1807-1808.
37. Laor E, Schiffman ZJ, Braunstein JD, et al. Androgen receptors in bladder tumors. Urology. 1985;25:161-163.
38. Kirkali Z, Cowan S, Leake RE. Androgen receptors in transitional cell carcinoma. Int Urol Nephrol. 1990;22:231-234.
39. Hebert JR, Miller DR. A cross-national investigation of diet and bladder cancer. Eur J Cancer. 1994;30A:778-784.
40. Okajima E, Hiramatsu T, Iriya K, Ijuin M, Matsushima S. Effects of sex hormones on development of urinary bladder tumours in rats induced by N-butyl-N-(4-hydroxybutyl) nirosamine. Urol Res. 1975;3:73-79.
41. Imada S, Akaza H, Ami Y, Koiso K, Ideyama Y, Takenaka T. Promoting effects and mechanisms of action of androgen in bladder carcinogenesis in male rats. Eur Urol. 1997;31:360-364.
42. Imaoka S, Yoneda Y, Sugimoto T, et al. Androgen regulation of CYP4B1 responsible for mutagenic activation of bladder carcinogens in the rat bladder: detection of CYP4B1 mRNA by competitive reverse transcription-polymerase chain reaction. Cancer Lett. 2001;166:119-123.